Betta Pharmaceuticals Valuation Multiples

Discover Betta Pharmaceuticals' revenue and EBITDA valuation multiples and investment history, alongside public comparables like Hubei Jumpcan, Zhejiang Huahai, Arcutis Biotherapeutics, Hualan Biological Engineering and more.

Betta Pharmaceuticals Overview

About Betta Pharmaceuticals

Betta Pharmaceuticals Co Ltd is a pharmaceutical enterprise that focuses on the research and development of innovative medicines. The company's drug is used for various diseases such as malignant tumors, diabetes, and cardio-cerebrovascular disease. Further, it offers Icotinib hydrochloride, an orally administered small-molecule and a reversible tyrosine kinase inhibitor, which is used for the treatment of non-small-cell lung cancer. Geographically, the group operates in China.


Founded

2003

HQ

China

Employees

N/A

Financials (LTM)

Revenue: $587M
EBITDA: $196M

EV

$3.9B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Betta Pharmaceuticals Financials

Betta Pharmaceuticals reported last 12-month revenue of $587M and EBITDA of $196M.

In the same LTM period, Betta Pharmaceuticals generated $471M in gross profit, $196M in EBITDA, and $76M in net income.

Revenue (LTM)


Betta Pharmaceuticals P&L

In the most recent fiscal year, Betta Pharmaceuticals reported revenue of $533M and EBITDA of $159M.

Betta Pharmaceuticals is profitable as of last fiscal year, with gross margin of 80%, EBITDA margin of 30%, and net margin of 8%.

See analyst estimates for Betta Pharmaceuticals
LTMLast FY202320242025202620272028
Revenue$587M$533M$363M$427M$533M
Gross Profit$471M$424M$303M$347M$424M
Gross Margin80%80%84%81%80%
EBITDA$196M$159M$100M$120M$154M
EBITDA Margin33%30%28%28%29%
EBIT Margin18%16%14%17%16%
Net Profit$76M$45M$51M$59M$45M
Net Margin13%8%14%14%8%
Net Debt-$162M---

Financial data powered by Morningstar, Inc.

Betta Pharmaceuticals Stock Performance

Betta Pharmaceuticals has current market cap of $3.6B, and enterprise value of $3.9B.

Market Cap Evolution


Betta Pharmaceuticals' stock price is $8.55.

Betta Pharmaceuticals share price decreased by 10.7% in the last 30 days, and by 8.8% in the last year.

Betta Pharmaceuticals has an EPS (earnings per share) of $0.11.

See more trading valuation data for Betta Pharmaceuticals
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$3.9B$3.6B0.0%-10.7%12.6%-8.8%$0.11

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Betta Pharmaceuticals Valuation Multiples

Betta Pharmaceuticals trades at 6.6x EV/Revenue multiple, and 19.8x EV/EBITDA.

See NTM and 2027E valuation multiples for Betta Pharmaceuticals

EV / Revenue (LTM)


Betta Pharmaceuticals Financial Valuation Multiples

As of July 19, 2026, Betta Pharmaceuticals has market cap of $3.6B and EV of $3.9B.

Betta Pharmaceuticals has a P/E ratio of 47.0x.

LTMLast FY202320242025202620272028
EV/Revenue6.6x7.3x10.7x9.1x7.3x
EV/EBITDA19.8x24.5x38.7x32.5x25.3x
EV/EBIT37.5x45.2x79.4x52.9x45.2x
EV/Gross Profit8.3x9.2x12.9x11.2x9.2x
P/E47.0x79.8x70.0x60.5x79.8x
EV/FCF-89.5x(145.0x)n/m89.5x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Betta Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Betta Pharmaceuticals Margins & Growth Rates

Betta Pharmaceuticals grew revenue by 19% and EBITDA by 43% in the last fiscal year.

In the most recent fiscal year, Betta Pharmaceuticals reported gross margin of 80%, EBITDA margin of 30%, and net margin of 8%.

See estimated margins and future growth rates for Betta Pharmaceuticals

Betta Pharmaceuticals Margins

Last FY202420252026202720282029
Gross Margin80%81%80%81%
EBITDA Margin30%28%29%36%
EBIT Margin16%17%16%19%
Net Margin8%14%8%16%
FCF Margin8%3%8%-

Betta Pharmaceuticals Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth19%18%25%19%
Gross Profit Growth21%15%22%21%
EBITDA Growth43%19%28%48%
EBIT Growth42%50%17%42%
Net Profit Growth128%16%(24%)128%
FCF Growth-(146%)252%-

Data powered by FactSet, Inc. and Morningstar, Inc.

Betta Pharmaceuticals Operational KPIs

Betta Pharmaceuticals' Rule of 40 is 55% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Betta Pharmaceuticals' Rule of X is 84% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Betta Pharmaceuticals
LTMLast FY202320242025202620272028
Rule of 4052%55%---
Bessemer Rule of X80%84%---
S&M Expenses to Revenue36%36%23%27%26%
G&A Expenses to Revenue13%13%5%1%3%
R&D Expenses to Revenue15%14%26%17%14%
Opex to Revenue-63%70%64%63%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Betta Pharmaceuticals Competitors

Betta Pharmaceuticals competitors include Hubei Jumpcan, Zhejiang Huahai, Arcutis Biotherapeutics, Hualan Biological Engineering, Yuhan, Organon, Alumis, Beijing Tiantan, Kolon TissueGene and Livzon Pharmaceutical Group.

Most Betta Pharmaceuticals public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Hubei Jumpcan2.0x2.0x5.0x-
Zhejiang Huahai3.6x3.5x18.3x16.4x
Arcutis Biotherapeutics9.2x7.8x325.4x83.0x
Hualan Biological Engineering4.5x4.5x14.0x13.9x
Yuhan2.3x2.3x17.0x27.7x
Organon1.8x1.8x5.8x5.9x
Alumis131.7x209.1x(12.7x)(9.9x)
Beijing Tiantan3.7x4.0x10.2x12.6x

This data is available for Pro users. Sign up to see all Betta Pharmaceuticals competitors and their valuation data.

Start Free Trial

Investments by Betta Pharmaceuticals

Betta Pharmaceuticals has invested in 6 companies to date.

Latest investment by Betta Pharmaceuticals was on January 9th 2026. Betta Pharmaceuticals invested in Zhixing Pharmaceutical in their $7M Secondary round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Betta Pharmaceuticals

Zhixing Pharmaceutical
Reprogenix
E-nitiate Biopharmaceuticals
Capio Biosciences
Description
Zhixing Pharmaceutical is a company specializing in research, development, and production of high-end inhaled formulations for respiratory therapies using advanced drug delivery technologies.
Reprogenix is a biotechnology company advancing stem cell therapies starting with type 1 diabetes treatment. The firm develops allogeneic mesenchymal stem cell products to restore insulin production and expand applications to autoimmune and degenerative diseases. Headquartered in the United States, Reprogenix conducts preclinical studies and clinical trials targeting beta cell regeneration through proprietary cell manufacturing processes.
E-nitiate Biopharmaceuticals is a China-based developer of therapies for autoimmune diseases through independent R&D and collaborations. The company advances drug candidates targeting rheumatoid arthritis, lupus, and inflammatory conditions.
Capio Biosciences is a biotechnology firm developing the CapioCyte platform for circulating tumor cell capture from whole blood samples. The technology employs biomimetic rolling and dendrimer-based multivalent binding to achieve higher sensitivity than competing methods, enabling downstream analyses like FISH, RNA-Seq, and NGS for oncology research. Capio Biosciences targets applications in cancer diagnostics and personalized treatment monitoring.
HQ CountryChinaChinaChinaUnited States
HQ City
-
Hangzhou
Hangzhou
Madison, WI
Deal Date9 Jan 20264 Nov 202431 Aug 20225 Jan 2017
RoundSecondarySeries AAngelSeries A
Raised$7M$14M$3M$3M
InvestorsBetta PharmaceuticalsBetta Pharmaceuticals; China Venture Capital; BeiChen Venture Capital Management; Lenovo Capital and Incubator Group (LCIG); Lotus Lake VenturesBetta PharmaceuticalsBetta Pharmaceuticals
Valuationundisclosedundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Betta Pharmaceuticals investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Betta Pharmaceuticals

When was Betta Pharmaceuticals founded?Betta Pharmaceuticals was founded in 2003.
Where is Betta Pharmaceuticals headquartered?Betta Pharmaceuticals is headquartered in China.
Who is the CEO of Betta Pharmaceuticals?Betta Pharmaceuticals' CEO is Lieming Ding.
Is Betta Pharmaceuticals publicly listed?Yes, Betta Pharmaceuticals is a public company listed on Shenzhen Stock Exchange.
What is the stock symbol of Betta Pharmaceuticals?Betta Pharmaceuticals trades under 300558 ticker.
When did Betta Pharmaceuticals go public?Betta Pharmaceuticals went public in 2016.
Who are competitors of Betta Pharmaceuticals?Betta Pharmaceuticals main competitors include Hubei Jumpcan, Zhejiang Huahai, Arcutis Biotherapeutics, Hualan Biological Engineering, Yuhan, Organon, Alumis, Beijing Tiantan, Kolon TissueGene, Livzon Pharmaceutical Group.
What is the current market cap of Betta Pharmaceuticals?Betta Pharmaceuticals' current market cap is $3.6B.
What is the current revenue of Betta Pharmaceuticals?Betta Pharmaceuticals' last 12 months revenue is $587M.
What is the current revenue growth of Betta Pharmaceuticals?Betta Pharmaceuticals revenue growth (NTM/LTM) is 19%.
What is the current EV/Revenue multiple of Betta Pharmaceuticals?Current revenue multiple of Betta Pharmaceuticals is 6.6x.
What is the current EBITDA of Betta Pharmaceuticals?Betta Pharmaceuticals' last 12 months EBITDA is $196M.
What is Betta Pharmaceuticals' EBITDA margin?Betta Pharmaceuticals' last 12 months EBITDA margin is 33%.
What is the current EV/EBITDA multiple of Betta Pharmaceuticals?Current EBITDA multiple of Betta Pharmaceuticals is 19.8x.
How many companies Betta Pharmaceuticals has acquired to date?Betta Pharmaceuticals hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Betta Pharmaceuticals has invested to date?As of July 2026, Betta Pharmaceuticals has invested in 6 companies.
What was the last Betta Pharmaceuticals investment?On 9th January 2026 Betta Pharmaceuticals invested in Zhixing Pharmaceutical, participating in a $7M Secondary round.

See public comps similar to Betta Pharmaceuticals

Lists including Betta Pharmaceuticals

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial